Arzneimittel | List of Frontiers open access articles

Review

Published on 22 Aug 2024

Pharmacological profile of dicaffeoylquinic acids and their role in the treatment of respiratory diseases

in Respiratory Pharmacology

Matthias Hufnagel
André Rademaekers
Anika Weisert
Hanns Häberlein
Sebastian Franken

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1371613

4,429 views
14 citations

Original Research

Published on 30 Mar 2023

Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients

in Cardiovascular and Smooth Muscle Pharmacology

A. Elif Müderrisoglu
Ayse A. Sakul
Sandra Murgas
Jean J. M. C. H. de la Rosette
Martin C. Michel

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1144470

3,508 views
12 citations

Clinical Trial

Accepted on 13 Feb 2026

A Randomized, Unblinded, Controlled Clinical Study to Assess the Mobile Digital Health Application INKA in the Management of Therapy Refractory Overactive Bladder and Mixed Incontinence

in Health Communications and Behavior Change

Lukas Schramm
Andreas Wiedemann
Claudia Neumesiter
Heike Wolf
Marcus Rudolf Götz
Christine Neubauer
Axel Hegele
Ralf Eckert
Laila Najjari
Johannes Salem

Frontiers in Digital Health

Review

Published on 16 Aug 2023

The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update

in Cellular Biochemistry

Tubanur Çetinarslan
Lisa Kümper
Regina Fölster-Holst

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2023.1159404

18,525 views
59 citations

Study Protocol

Published on 11 Aug 2022

Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial – Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial

in Translational Medicine

Petra Huehnchen
Nikola Bangemann
Sandra Lischewski
Stefanie Märschenz
Friedemann Paul
Tanja Schmitz-Hübsch
Jens-Uwe Blohmer
Cornelia Eberhardt
Geraldine Rauch
Agnes Flöel

Frontiers in Medicine

doi 10.3389/fmed.2022.967964

6,527 views
8 citations

Policy Brief

Published on 26 Jan 2026

Designing integrated early-phase protocols to reduce substantial modifications, including considerations for patient cohorts – a multi-stakeholder consensus view for a practical approach in Germany

in Drugs Outcomes Research and Policies

R. Schultz-Heienbrok
S. Baumann
R. Böhm
A. Bonertz
K. Breithaupt-Groegler
U. Buckpesch-Heberer
M. Coenen
K. Erb-Zohar
N. Faisst
G. Grass

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1699906

1,126 views

Perspective

Published on 19 Nov 2021

The EU Response to the Presence of Nitrosamine Impurities in Medicines

in Regulatory Science

Robin Ruepp
Roland Frötschl
Robert Bream
Maria Filancia
Thomas Girard
Andrei Spinei
Martina Weise
Rhys Whomsley

Frontiers in Medicine

doi 10.3389/fmed.2021.782536

19,829 views
27 citations

Original Research

Published on 30 Jun 2022

Anti-Inflammatory Potential of Phenolic Compounds Isolated From Entada africana Guill. & Perr. Used in the Republic of Benin

in Ethnopharmacology

Nonvignon Murielle Codo Toafode
Peter Marquardt
Virgile Ahyi
Karin Fester
Verena Spiegler
Cica Vissiennon

Frontiers in Pharmacology

doi 10.3389/fphar.2022.931240

6,086 views
6 citations

Review

Published on 26 Jan 2021

Role of Cardiac A2A Receptors Under Normal and Pathophysiological Conditions

in Cardiovascular and Smooth Muscle Pharmacology

P. Boknik
J. Eskandar
B. Hofmann
N. Zimmermann
J. Neumann
U. Gergs

Frontiers in Pharmacology

doi 10.3389/fphar.2020.627838

7,432 views
29 citations

Policy and Practice Reviews

Published on 27 Aug 2021

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective

in Regulatory Science

Maria E. Sheean
Frauke Naumann-Winter
Giuseppe Capovilla
Maria Elisabeth Kalland
Eva Malikova
Segundo Mariz
Darius Matusevicius
Robert Nistico
Brigitte Schwarzer-Daum
Stelios Tsigkos

Frontiers in Medicine

doi 10.3389/fmed.2021.744625

6,980 views
6 citations

Original Research

Published on 10 Jul 2025

Multistakeholder scientific advice for medicinal products used in combination with a medical device or a companion diagnostic in the EU—summary of a Focus group discussion

in Regulatory Science

Stiina Aarum
Claudia Popp
Alexa Hunter
Miha Skvarc
Ilona Reischl
Hilke Zander
Joerg Zinserling
Petra van Leeuwen
Jonathan Sutch
Tim Chesworth

Frontiers in Medicine

doi 10.3389/fmed.2025.1593644

4,935 views
1 citation

Original Research

Published on 22 Jan 2018

Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors

in Experimental Pharmacology and Drug Discovery

Peter Boknik
Katharina Drzewiecki
John Eskandar
Ulrich Gergs
Stephanie Grote-Wessels
Larissa Fabritz
Paulus Kirchhof
Frank U. Müller
Frank Stümpel
Wilhelm Schmitz

Frontiers in Pharmacology

doi 10.3389/fphar.2018.00013

4,103 views
34 citations

Original Research

Published on 18 Sep 2019

Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors

in Experimental Pharmacology and Drug Discovery

Peter Boknik
Katharina Drzewiecki
John Eskandar
Ulrich Gergs
Britt Hofmann
Hendrik Treede
Stephanie Grote-Wessels
Larissa Fabritz
Paulus Kirchhof
Lisa Fortmüller

Frontiers in Pharmacology

doi 10.3389/fphar.2019.01051

3,993 views
27 citations

Articles

Pharmacological profile of dicaffeoylquinic acids and their role in the treatment of respiratory diseases

Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients

A Randomized, Unblinded, Controlled Clinical Study to Assess the Mobile Digital Health Application INKA in the Management of Therapy Refractory Overactive Bladder and Mixed Incontinence

The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update

Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial – Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial

Designing integrated early-phase protocols to reduce substantial modifications, including considerations for patient cohorts – a multi-stakeholder consensus view for a practical approach in Germany

The EU Response to the Presence of Nitrosamine Impurities in Medicines

Anti-Inflammatory Potential of Phenolic Compounds Isolated From Entada africana Guill. & Perr. Used in the Republic of Benin

Role of Cardiac A2A Receptors Under Normal and Pathophysiological Conditions

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective

Multistakeholder scientific advice for medicinal products used in combination with a medical device or a companion diagnostic in the EU—summary of a Focus group discussion

Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors

Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors